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Purpose: To investigate clinical, biochemical and radiological features in 35 patients with adrenal inci-
dentaloma found on CT and/or MRI and to deﬁne the management of patients with adrenal masses.
Matherial and methods: From January 2011 and May 2013, 35 patients (19F, 16M) with an adrenal mass
incidentally discovered on CT and/or MRI were enrolled in a retrospective study. Thirthy-two patients
underwent MDCT and eight 1.5 MRI.
Results: Patients consisted in 16 males and 19 females, aged between 25 and 89 yo. Adrenal lesions were
most commonly found in the sixth decade; in relation to the side of the mass, 20 were found on left side,
15 on the right. Of all the mass analyzed, 3 were <1 cm diameter, 29 between 1 and 4 cm, 3 > 4 cm. The
most common ﬁnding on CT was adenoma-like appearance (19 cases in relation to size, 14 in relation to
attenuation values). Hormonal analysis showed 32 cases of nonfunctional masses and 3 cases of hormone
activity. Adrenalectomy was performed in ten patients having adenoma (5 cases), malignant lesions (2
cases), pheocromocitoma, cyst and myelolipoma (1 case).
Conclusion: Diagnostic approach to adrenal incidentaloma is focused on the deﬁnition of malignancy and
hormonal activity; the characterization is needs hormonal and radiological (CT and/or MRI) evaluation,
even if a ﬁne needle aspiration is needed in selected cases.
Benign and/or non-hypersecreting hormone lesion with <4 cm diameter could be sent to follow-up;
active adrenal tumors or >4 cm diameter lesions with malignancy suspicious or growth during
follow-up could be treated with surgical adrenalectomy.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Adrenal lesions greater than 1 cm detected during non-invasive
abdominal imaging techniques performed for unrelated reasons are
called “adrenal incidentaloma” or “diseases of modern technology”.
The frequency of adrenal incidentaloma has grown with the
advancements in imaging technology (US, CT, MRI and scintig-
raphy); the prevalence increases with age [1], although the higher
incidence is reported between 50 and 70 years mainly in patients
with diabetes mellitus, hypertension and obesity; there is no dif-
ference in prevalence based on race and sex.
The incidence of adrenal nodules at autopsy is between 8.7% [1]
and 32% of patients without suspicion of adrenal disease [2e4].inelli).
by Elsevier Ltd. All rights reservedThe differential diagnosis includes non-hypersecreting adrenal
adenoma, hypersecreting adrenal adenoma (Subclinical Cushing’s
syndrome, pheocromocitoma, primary aldosteronism), primary
adrenal carcinoma, metastases and other adrenal masses (myelo-
lipoma, cyst or ganglioneuroma).
Diagnostical approach includes the differentiation between
benign/malignant lesions and functional/nonfunctional lesions; it
requires a clinical and biochemical work-up. 80% of adrenal lesions
is non-hypersecreting adenoma, with size less than 2 cm [1].
It is necessary to know if the patient has a present or past cancer
diagnosis, because in these patients the incidence of malignancy is
between 30 and 50% [5]; in patients without history of cancer,
malignancy is very rare. There is a correlation also between ma-
lignancy and size of the lesion: malignancy suspection increases
with the mass diameter [6e8].
Surgery is indicated only in a small fraction of cases, because
small and hormonally inactive lesions predominates among sus-
pected masses..
Table 1
Characteristics of 35 adrenal incidentaloma.
Characteristics No
Age (yo)
<40 3
40e50 7
50e60 12
60e70 10
>70 3
Sex
Male 16
Female 19
Site
Right 15
Left 20
Bilateral 0
Functionality
Yes 3
No 32
Exams
CT 27
MRI 3
CT and MRI 5
Scintigraphy 1
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radiological features in 35 patients with adrenal incidentaloma
found on CT and/or MRI and to deﬁne the management of patients
with adrenal masses.
2. Matherial and methods
2.1. Study population
From January 2011 andMay 2013, 35 patients (19F,16M)with an
adrenal mass incidentally discovered on CT and/or MRI were
enrolled in a retrospective study.
No subjects who had adrenal mass discovered on these exams
presented adrenal symptoms; they had underwent diagnostic
exams for other causes, such as abdominal hernias, cholecystitis,
other urinary or abdominal symptoms.
Demographic characteristics collected for patients were: sex,
age, medical history, diameter and side of the lesion, endocrine
function, follow-up and/or histological ﬁndings of surgical
adrenalectomy.
We also evaluated Hounsﬁeld Units (HU), before and after
contrast media administration in benign and malignant lesions at
CT exams and Absolute Chemical Shift on MRI.
In relation to endocrine functionality, all patients underwent to
hormone tests relating to pheocromocytoma, subclinical Cushing’s
syndrome, aldosterone primary adenoma.
2.2. Imaging
Thirthy-two patients underwent MDCT (Toshiba, Aquilion 4,
Tokyo, Japan) and 8 1.5 MRI (Siemens Symphony 1.5 Erlangen,
Germany).
2.2.1. MDCT
The patient was moved to the CT room where scout-view and
volumetric scanwere carried out. A layer nowider than 3mm and a
reconstructing interval no larger than 5mmwere chosen (kVp: 120,
mA: 250; pitch 1).
Iodinated contrast agent was injected intravenously, 1.5 ml
iodine/kg body weight (BW) through a mechanic injector at a
concentration of 400 mg iodine/mL (contrast agents “Iomeprol”
and ‘‘Iomeron 400" developed by the Italian pharmaceutical com-
pany Bracco) and a ﬂow speed of 2.5 ml/s. The dedicated exami-
nation protocol comprise a precontrast CT and two post-contrast
scanning (at 35 s and a delayed scanning at 10 min after contrast
media injection started).
2.2.2. MRI
All MRI imaging studies were performed on 1.5-T closed magnet
(Magnetom Symphony, Siemens, Germany). All patients were su-
pine imaged with a body-phased-array receiver coil.
After an initial localizer in three different planes, the study
protocol included:
- T2-W Haste Multiple Breath Hold (MBH), T1-W ﬂ2d in-out of
phase, T1-W ﬂ2D Fat suppressed on axial plase; T2-W Haste
MBH, T2-W Truﬁ BH on coronal plane;
- T1-W FLASH 3D Fat suppressed in axial plane, before contrast
media administration;
- 4 sequential scans with 20 s interval and tardive acquisition
10min after (T1-W FLASH 3D Fat Suppressed in axial plane after
Gd-DTPA (0.1 mmol/kg).
During post-processing examination, Region of Interest (ROI)
were used for densitometric evaluation on CT exam and signalintensity in in-out of phase MRI; ROI were realized in relation to
lesion diameter excluding calciﬁcations and or ﬂuid areas on CT
and/or MRI.
ROI value of intensity signal on T1-W ﬂ2d in-out phase to
calculate Absolute Chemical Shift (ACS) were included in the form:
½ðSIIPSIOPÞ=SIIP100
½SIIP :signalintensityinphase; SIOP : signalintensityoutof phase
3. Results
Of 35 patients, three were <40 yo, seven between 40 and 50 yo,
twelve between 50 and 60 yo, ten between 60 and 70 yo, 3 over
>70 yo. Adrenal lesions are more frequent in the age between 50
and 70 yo.
There were 19 females, 16 males; 27 patients underwent MDCT,
3MRI, 5 underwentMDCTandMRI and one patient underwent also
scintigraphy.
Of the 35 lesions detected, 20 were on left side, 15 on the right
side; no bilateral lesions were detected; 3 were functional, 32 were
nonfunctional masses (Table 1).
In relation to lesion diameter, 3 were <1 cm, 29 with a size
between 1 and 4 cm, 3 presented a diameter >4 cm.
The location, size and shape of lesions were determined with CT
andMRI and it was found that 19 subjects had features of adenoma;
18 of these 19 patients were less than 4 cm in size.
Cushing syndrome was detected in 4 patients, pheocromoci-
toma in 5, malign lesion and myelolipoma in one case (Table 2).
Measurement of HU by nonenhanced CT yielded 7 subjects and
3 subjects out of 14 patients with adenoma-like appearance with
less than 10 HU and over 20 HU, respectively.
Conversely, measurement less than 10 HU and between 10 and
20 HU were observed in the two patients with pheocromocitoma-
like appearance lesions (Table 3).
Semiquantitative study of Pre and Postcontrast media injection
on MDCT at 35 s (wash in) and 10 min (wash-out) and absolute
Chemical Shift in MRI with a cut-off of 16.5%, demonstrated sub-
stantial differences, as shown in Table 4.
Patients with <4 cm diameter adrenal lesions, with endocrine
negative tests, were sent to follow-up with CT after 3e6 months
and then every year for three years with endocrine reevaluation
every year.
Table 2
Distribution of clinical diagnosis by mass size.
Diagnosis TOT <1 cm 1 cm >4 cm
Adenoma 19 2 16 1
Subclinical cushing’s syndrome 4 4
Primary aldosteronism 3 3
Pheocromocitoma 5 1 3 1
Malignant lesion 2 1 1
Myelolipoma 1 1
Cyst 1 1
Other 0
Total 35 3 29 3
Table 4
HU on pre and post contrast media injection on MDCT. (WI: wash in at 35sec and
WO: wash out at 10 min); Absolute Chemical Shift (ACS) and ACS cut-off on CSI
eMRI.
MDCT CSI MRI
Precontrast HU WI (35 s ) WO (10 min) ACS (%) ACS
cut-off (%)
Benign lesions 14 ± 8 70 ± 24 33 ± 21 84 ± 6 16.5
Malignant
lesions
32.9 ± 7 38.7 ± 15 10.4 ± 8 10 ± 19 <16.5
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and density or intensity regular shape and patients with >4 cm
lesionwith positive endocrine tests or increase in tumor size during
follow-up were sent to surgical adrenalectomy.
Of ten patients underwent surgical adrenalectomy, adenoma
was themost frequent case, with 5 lesions, followed by 2 cases with
malignant lesion, 1 case of pheocromocitoma, 1 of cyst and 1 of
myelolipoma.
A total of two patients underwent surgery as treatment for
functional masses, three for suspected malignancy, one for lesion
size (>4 cm), and four underwent adrenalectomy concurrent with
nonadrenal surgery (Table 5).
4. Discussion
The diagnostic approach of adrenal incidentaloma aims to
determine the type of mass and focuses of hormonal activity and
malignancy suspicious.
4.1. Clinical manifestation
First, a meticulous history is necessary to deﬁne hyper, non-
hypersecreting lesions, primary adrenal carcinoma, other adrenal
masses (myelolipoma, cysts, ganglioneuroma) and metastases.
80% of adrenal incidentaloma are asymptomatic with a size less
than 2 cm; in symptomatic lesions, clinical manifestations depends
on the type of hormone being secreted by the tumor.
Beacuse 20% of adrenal incidentaloma was asymptomatic hor-
mone hypersecreting tumor, the National Institute of Health sug-
gests to consider all adrenal incidentaloma as hypersecreting
tumor, even without clinical manifestation until otherwise proven
by hormonal tests [3,9e14]. In addition, the probability of hyper-
secreting hormone tumor increases with themass diameter. With a
40% of hypersecreting lesions with >6 cm diameter.
4.2. Laboratory tests
24-h urinary cathecolamines and 1 mg dexamethasone sup-
pression test are performed in patients with imaging diagnosis ofTable 3
Distribution of clinical diagnosis by UH.
Diagnosis TOT <10 UH 10e20 UH >20 UH
Adenoma 14 7 4 3
Subclinical cushing’s syndrome 4 2 1 1
Primary aldosteronism 6 3 2 1
Pheocromocitoma 2 1 1 e
Malignant lesion 5 3 e 2
Myelolipoma 2 1 1 e
Cyst 1 e e 1
Other 1 e e 1
Total 35 16 9 10adrenal incidentaloma; in patient with hypertension, aldosterone/
plasma renin activity ratio is also recommended [2,12e15].
Due to the small number of prevalence of sex-hormone hyper-
secreting tumor, routine test for sex hormone is not indicated
[16e21].
4.3. Imaging techniques
After clinical evaluation and laboratory tests, it is necessary the
re-evaluation of imaging features of adrenal masses.
4.3.1. MDCT
Abdomen MDCT is the best choice, especially in relation to cost-
effective; the dedicated examination protocol for the character-
ization of adrenal incidentaloma comprise a pre-contrast CT and
two post-contrast scanning (after 35 s and 10 min) [22e25]; in the
local practice the post-contrast phases could be performed at
different times (90e120 s and 10e15 min) [5].
Homogeneous lesion with smooth margins and size less than
4 cm and density <10 HU without enhancement to contrast media,
indicates benign lesions [26e28], with a speciﬁcity of 98e99%
[29,30]; the presence of macroscopic fat, with a density of 10’ HU
is characteristic of a myelolipoma; if the attenuation is of 0e15 HU
without enhancement after contrast media administration, a sim-
ple cyst is suspected [5].
Adrenal lesions with the same attenuation values and an ade-
noma and/or a cyst appearance with a transverse diameter >4 cm,
no further imaging is needed [30]. Tumor size, indeed, is only a
supplementary element in CT scan and should not be used as the
only element for therapeutic approach [31]; only changes in tumor
size during follow-up represent an indication for tumor resection.
On the opposite, precontrast HU value >10 requires information
about contrast-enhanced and wash-out. Moderate enhancement
followed by a rapid contrast agent washout from the tumors occurs
in adenomas [31e33].
Malignant lesions are poor vascularized and have larger inter-
stitial spaces with high pressure; these features prevent the
contrast enhancement and delay the contrast medium wash-out
[31,34].
On the other side, disomogeneous lesions with irregular shapes,
size more than 4 cm, density >10HU and marked enhancementTable 5
Characteristics of 10 adrenalectomy with a hystopathologic diagnosis proven by
surgery.
>4 cm Functional
mass
Suspected
malignancy
(>20 UH)
Concomitant
surgery
TOT
Adenoma e 1 e 4 5
Pheocromocitoma e 1 e e 1
Malignancy 1 e 1 e 2
Cyst e e 1 e 1
Myelolipoma e e 1 e 1
Tot 1 2 3 4 10
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myld adenoma or myelolipomas could present inhomogeneity and
pheocromocytomas could also contain necrotic areas and calciﬁ-
cations and could present slow wash-out in 10e15 min post-
contrast media administration [36].
Usually, a threshold of 10 HU and 24 HU with a 14-min delay on
contrast-enhanced CT scan is considered the cut-off to distinguish
between adenomas and metastases.
An absolute wash-out in a scanning with a post-contrast delay
of 15 min <0.6 indicates a malignant lesion; if the value is >0.6 the
lesion may be benign [34,37e39]; in our experience a wash-out HU
value of 33 ± 21 is indicative of benign lesions, a value of 10.4 ± 8
is typical of a malignant lesion.
However, in the wash-out calculations, the attenuation mea-
surements may vary depending on technical parameters, such as
partial volume effects and how the Region of Interest (ROI) is drawn
and positioned.
4.3.2. MRI
MRI is superior than MDCT in the characterization of pheocro-
mocitoma and carcinoma inﬁltration.
Malignant lesions show low signal intensity on T1-weighted
images and high signal intensity on T2-weighted images with
strong enhancement and slow washout after contrast media
administration; benign lesions usually presents isointense or low
signal intensity on T1 and T2 weighted images and rapid contrast
and washout after contrast media administration [40e42].
On T2-weighted images 30% of lesions presents overlapping
between benign and malign tumor appearance, such as adrenal
carcinoma and metastatic lesions.
The presence of calciﬁcations, necrosis and hemorrage is sus-
picious but not pathognomonic for malignant lesions.
This imaging method has the same diagnostic accuracy of MDCT
in the evaluation of the spread of the tumor into liver, lymph node
and lung, but is better than MDCT in the evaluation of near tissue
inﬁltration, particularly into the inferior cava vein [43,44]. The only
limitation is due to the lower spatial resolution in the character-
ization of very small lesions.
The “in-phase” and “out-of-phase” T1 weighted GRE sequences
deﬁne the Chemical Shift Phoenomenon (CSI) [25] because of the
microscopic fat and water intensity signal in phase decreases in out
of phase sequences. CSI could be a useful tool to differentiate
benign frommalignant lesions, even if some benign lesions, such as
“lipid-poor adenomas” will escape this characterization. Trace of
lipids could be detected also in adrenal carcinoma, but not in
pheocromocitoma and these features are useful to distinguish
carcinoma from pheocromocitoma [31].
4.3.3. Fine needle aspiration (FNA)
Ultrasound or, more frequently, CT-guided ﬁne needle aspira-
tion is a useful diagnostic tool in the evaluation of adrenal lesions
[45,46]. This method is reserved in patients in whom the presence
of adrenal metastases may modify therapy and/or prognosis; it is
not indicated in patients with adrenal incidentaloma without risk
factors for malignancy [15].
FNA may identify metastases, but it cannot differentiate ade-
noma from primary adrenal carcinoma [47].
If a pheocromocitoma is suspected, FNA is not indicated,
because the procedure could determine hypertensive crisis or
sudden death [1].
4.3.4. Management
The management of adrenal incidentaloma is still controversial
because the clinician is called upon to devise a cost-effectiveapproach taking into account the extensive endocrine work-up
and radiological investigations that may be necessary [48].
A screening evaluation should be performed to exclude a func-
tioning adrenal tumor in all patients with adrenal incidentaloma.
Although by deﬁnition an incidentaloma is a clinically silent.
Mass, a careful investigation including family history and physical
examination must be performed, followed by assessing the char-
acteristics of the tumor, whether it is hormonally active or ma-
lignant [22,45]. An overnight low dose dexamethasone
suppression test, the measurement of 24-h urinary catechol-
amines or metanephrines, serum potassium and, in hypertensive
patients, upright plasma aldosterone/PRA ratio. DHEAS measure-
ments may show evidence of adrenal androgen excess. Positive
results should be followed by speciﬁc hormonal evaluations for a
deﬁnitive diagnosis [15].
Laparoscopic adrenalectomy is the best choice for hormone
hypersecreting type of adrenal incidentaloma with typical symp-
toms in patients with adrenal incidentaloma, especially if the tu-
mor types are Conn’s disease and pheochromocytoma [1,45].
Although the natural history of Subclinical Cushing's Syndrome
and its morbidity are unclear, we advocate adrenalectomy for pa-
tients with this condition, especially in the presence of clinical
problems (metabolic disorder such as insulin resistance, or even
progressing to Cushing’s syndrome) potentially aggravated by
glucocorticoid excess [49].
The size of adrenal incidentaloma can be a parameter in
differentiating benign and malignant tumor, although it is hor-
monally inactive.
The size of tumor is measured by CTorMRI. Tumor with size less
than 4 cm is generally benign and adrenalectomy is not recom-
mended; however, repeated CT scan is needed every 3e6 months
on the ﬁrst year and every year for 3 years period, and hormonal re-
evaluation should be performed annually; then hormonal and
radiological evaluation should be performed after 1 year, then
every 1e2 years for a period which awaits to be deﬁned by
oncoming data from long-term follow-up of large series [50e52].
If hormonal status becomes active or the size of the tumor in-
creases, then adrenalectomy is performed.
In patients with extra-adrenal malignancy, in particular of the
lung, the AI (especially if bilateral) may be a metastasis. In this case,
an FNA biopsy should be performed [15].
Features suggestive of malignancy are large size, irregular
margins, non-homogeneous density and an attenuation value >20
HU on noncontrast-enhanced CT. According to our own experience
a mass larger than 4 cm should be surgically removed [15].
Adrenalectomy can be performed by methods of laparatomy or
laparoscopic. Tumor size and tumor malignancy status determine
the surgical method, even if laparoscopic treatment has lower
morbidity and mortality rate, ranges from 5 to 10% and 1e2%
[53,54].
If the tumor size is less than 10 cm, laparoscopic adrenalectomy
can be performed. If the tumor size is more than 10 cm, laparatomy
is suggested. The surgical method-of-choice for malignancy is
laparatomy [1,55].
Surgery is indicated also for lesions that grow signiﬁcantly in
diameter in the course of follow-up [12].
In conclusion, the prognosis of adrenal incidentaloma depends
on the tumor. The majority of adrenal incidentaloma is non-
hypersecreting tumor, with a good prognosis.
Approximately 20% of adrenal incidentaloma can develop into
hypersecreting tumor in 3e4 years period, particularly tumor with
size >3 cm [56].
The prognosis of hypersecreting tumor will get worse if no
surgical measure is taken, because the possible complication due to
hypersecreting hormone. Prognosis after surgical removal of
A. Reginelli et al. / International Journal of Surgery 12 (2014) S126eS131S130hypersecreting tumor is generally good, because the removal can
decrease cardiovascular risk such as hypertension, hyperglycemia
and hypercholesterolemia [56].
The prognosis of tumor metastases depends on histological
proﬁle, staging and location of the primary tumor. The worst
prognosis is for adrenocortical carcinoma with >6 cm diameter.
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